Is Compounded Semaglutide or Tirzepatide Still Legal in 2026?

Compounded semaglutide and tirzepatide are not universally banned, but an online offer does not establish that a particular prescription is lawful. The shortages have ended, and the broad shortage-based route for making copies has ended with them. A patient-specific formulation may qualify under section 503A when a prescriber determines and documents a change that makes a significant difference for that individual patient, and all other applicable conditions are met¹².

Compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness or quality before marketing. FDA recommends using compounded drugs only when a patient's medical needs cannot be met by an approved drug³. Lower price and a pharmacy license do not answer the separate question of whether a specific formula meets compounding requirements.

This guide reflects official sources read on October 14, 2026. For the historical dates, see GLP-1 shortage status. For the shopping checklist, see how to verify a compounding pharmacy.

503A vs 503B: the difference that matters

These are two federal frameworks, not grades of medicine. Neither makes a compounded product FDA-approved³.

Sources: FDA's compounding overview and GLP-1 policy clarification³¹. A facility's registration or license identifies the applicable framework; it does not settle whether its GLP-1 product qualifies.

For a patient considering 503A treatment: ask what change is being prescribed, why the approved option does not meet your needs, and how that determination is documented. FDA's guidance gives examples involving an ingredient allergy or a necessary strength change. It specifically does not treat a lower price as a significant difference².

For a program advertising 503B supply: ask about its legal basis for using bulk semaglutide or tirzepatide. FDA's April 2026 update says neither ingredient is on the 503B bulks list or the drug shortage list¹. A patient-specific rationale does not replace that separate bulk-ingredient condition.

What changed in 2025 and 2026

Sources: FDA's shortage-policy page, proposal, comment extension and warning letter¹⁴⁵⁶.

The April action is a proposal, not a new nationwide ban on every form of GLP-1 compounding. FDA said it would consider comments before its final determination. The official sources reviewed for this guide did not establish a later final determination⁴⁵. Existing restrictions still apply while a proposal is pending.

Adding B12 does not automatically make a formula different

FDA's September 18 letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, described semaglutide/cyanocobalamin and tirzepatide/niacinamide preparations that appeared to be essentially copies. The agency also questioned prescriptions with missing or repeated determinations of significant difference, including statements that appeared pre-generated for prescriber selection⁶.

That letter concerns one facility and specific inspection findings. It is not a finding against every pharmacy or every vitamin-containing prescription. Its consumer lesson is narrower: an added vitamin and a checkbox are not proof of individualized clinical need. FDA also reported sterile-production deficiencies in the letter, reinforcing why the formula's legal basis and the pharmacy's quality practices both matter⁶.

Semaglutide salts are a separate issue. FDA says semaglutide sodium and semaglutide acetate differ from the active ingredient in approved products and that it knows of no lawful basis for their use in compounding⁷. Ask for the exact ingredient, not only the marketing name.

What this means for a low monthly price

Compare access before committing to a long plan. A hypothetical $200 monthly program costs $2,400 for 12 calendar-month payments. If brand treatment costs $300 for the same billing periods, the apparent saving is $1,200. That arithmetic tells you the price gap; it tells you nothing about clinical suitability, lawful supply or what happens if the program stops offering your formula.

Before paying, get answers to four questions:

• Who fills the prescription? Get the pharmacy's legal name and confirm its license for your state.
• What is prescribed? Confirm the active ingredient, concentration, dose and any added ingredients.
• Why this formula for you? Have the prescriber explain the patient-specific reason rather than a general promise that it is cheaper.
• What happens if supply changes? Read cancellation, refund and transition terms, especially before paying for several months.

Those questions are a practical buying framework, not a determination that a pharmacy is compliant. Our pharmacy verification guide covers license and inspection checks, and compounded tirzepatide cost explains fees and billing periods.

Also compare the current approved-drug routes: Wegovy prices without insurance, Zepbound prices without insurance, and TrumpRx GLP-1 offers. A lower-priced approved option may change the value comparison. The semaglutide and tirzepatide program comparisons help identify costs to ask about; a listing is not a guarantee of availability or eligibility.

Can you still get compounded GLP-1 in your state?

There is no reliable national yes-or-no answer for every patient. The federal framework, the formula, the prescriber's determination, state requirements and the dispensing pharmacy all matter. A website accepting orders from your ZIP code does not resolve those questions. Confirm them with the prescriber and pharmacy before paying.

If you already use a compounded prescription, ask your clinician how current supply and prescribing requirements affect your next fill. The right next step depends on your treatment, rather than on a headline saying compounding has either ended completely or remains unrestricted.